Stanley Charles Erck's most recent trade in MaxCyte Inc was a trade of 50,790 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MaxCyte Inc | Stanley Charles Erck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 50,790 | 50,790 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Stanley Charles Erck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 29,210 | 298,328 | - | 0 | Common Stock | |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 01 Nov 2024 | 47,689 | 316,807 | - | 0.0 | 1,908 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 47,689 | 0 | - | - | Employee Stock Option (right to buy) | |
| MaxCyte Inc | Stanley Charles Erck | Director | Sale of securities on an exchange or to another person at price $ 3.72 per share. | 01 Nov 2024 | 47,689 | 269,118 | - | 3.7 | 177,403 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | 01 Nov 2024 | 47,689 | 247,751 (0%) | 0% | 3.7 | 177,198 | Ords 0.01p | |
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | 01 Nov 2024 | 47,689 | 295,440 (0%) | 0% | 0.0 | 1,908 | Ords 0.01p | |
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | 02 Oct 2024 | 21,607 | 247,751 (0%) | 0% | 0 | Ords | ||
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | 02 Oct 2024 | 21,607 | 269,358 (0%) | 0% | 0.0 | 864 | Ords | |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 26,082 | 69,296 | - | - | Employee Stock Option (right to buy) | |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 01 Oct 2024 | 26,082 | 295,200 | - | 0.0 | 1,043 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Director | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Oct 2024 | 26,082 | 269,118 | - | 3.8 | 98,590 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | 01 Oct 2024 | 26,082 | 247,751 (0%) | 0% | 0 | Ords | ||
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | 01 Oct 2024 | 26,082 | 273,833 (0%) | 0% | 0.0 | 1,043 | Ords | |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 21,607 | 47,689 | - | - | Employee Stock Option (right to buy) | |
| MaxCyte Inc | Stanley Charles Erck | Director | Sale of securities on an exchange or to another person at price $ 3.71 per share. | 01 Oct 2024 | 21,607 | 269,118 | - | 3.7 | 80,162 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 01 Oct 2024 | 21,607 | 290,725 | - | 0.0 | 864 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | Sale of securities on an exchange or to another person at price $ 3.97 per share. | 04 Sep 2024 | 29,767 | 247,751 (0%) | 0% | 4.0 | 118,133 | Ords 0.01p |
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | 04 Sep 2024 | 29,767 | 277,518 (0%) | 0% | 0.0 | 1,191 | Ords 0.01p | |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 29,767 | 95,378 | - | - | Employee Stock Option (right to buy) | |
| MaxCyte Inc | Stanley Charles Erck | Director | Sale of securities on an exchange or to another person at price $ 3.97 per share. | 03 Sep 2024 | 29,767 | 269,118 | - | 4.0 | 118,175 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 03 Sep 2024 | 29,767 | 298,885 | - | 0.0 | 1,191 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 03 Sep 2024 | 17,922 | 287,040 | - | 0.0 | 717 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 17,922 | 125,145 | - | - | Employee Stock Option (right to buy) | |
| MaxCyte Inc | Stanley Charles Erck | Director | Sale of securities on an exchange or to another person at price $ 4.10 per share. | 03 Sep 2024 | 17,922 | 269,118 | - | 4.1 | 73,480 | Common Stock |
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | Sale of securities on an exchange or to another person at price $ 4.10 per share. | 03 Sep 2024 | 17,922 | 247,751 (0%) | 0% | 4.1 | 73,441 | Ords 0.01p |
| MaxCyte Inc | Stanley Charles Erck | Non-Executive Director | 03 Sep 2024 | 17,922 | 265,673 (0%) | 0% | 0.0 | 717 | Ords 0.01p | |
| MaxCyte Inc | Stanley Charles Erck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 40,701 | 40,701 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Stanley Charles Erck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 21,367 | 269,118 | - | 0 | Common Stock | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2022 | 6,546 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2022 | 6,546 | 34,026 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.87 per share. | 26 Sep 2022 | 2,180 | 31,846 (0%) | 0% | 18.9 | 41,137 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 62,211 | 62,211 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 41,474 | 41,474 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 6,967 | 13,933 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 6,967 | 30,846 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 168.43 per share. | 14 Dec 2021 | 3,366 | 27,480 (0%) | 0% | 168.4 | 566,935 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2021 | 32,000 | 36,499 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.60 per share. | 04 Oct 2021 | 32,000 | 55,879 (0%) | 0% | 27.6 | 883,200 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.00 per share. | 04 Oct 2021 | 10,829 | 66,708 (0%) | 0% | 27 | 292,383 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2021 | 10,829 | 0 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 177.58 per share. | 04 Oct 2021 | 8,890 | 36,242 (0%) | 0% | 177.6 | 1,578,724 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 178.46 per share. | 04 Oct 2021 | 8,563 | 27,679 (0%) | 0% | 178.5 | 1,528,182 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 173.45 per share. | 04 Oct 2021 | 5,038 | 56,532 (0%) | 0% | 173.4 | 873,829 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 176.48 per share. | 04 Oct 2021 | 4,700 | 45,132 (0%) | 0% | 176.5 | 829,434 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 172.36 per share. | 04 Oct 2021 | 3,746 | 61,570 (0%) | 0% | 172.4 | 645,672 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 175.61 per share. | 04 Oct 2021 | 3,600 | 49,832 (0%) | 0% | 175.6 | 632,198 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 179.48 per share. | 04 Oct 2021 | 3,300 | 24,379 (0%) | 0% | 179.5 | 592,282 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 174.56 per share. | 04 Oct 2021 | 3,100 | 53,432 (0%) | 0% | 174.6 | 541,142 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 166.98 per share. | 04 Oct 2021 | 1,392 | 65,316 (0%) | 0% | 167.0 | 232,441 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 180.58 per share. | 04 Oct 2021 | 500 | 23,879 (0%) | 0% | 180.6 | 90,290 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 35,000 | 10,829 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.00 per share. | 01 Oct 2021 | 35,000 | 72,879 (0%) | 0% | 27 | 945,000 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 14,000 | 68,499 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.60 per share. | 01 Oct 2021 | 14,000 | 37,879 (0%) | 0% | 27.6 | 386,400 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 177.37 per share. | 01 Oct 2021 | 6,227 | 36,521 (0%) | 0% | 177.4 | 1,104,474 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 174.30 per share. | 01 Oct 2021 | 5,853 | 48,951 (0%) | 0% | 174.3 | 1,020,176 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 178.27 per share. | 01 Oct 2021 | 4,604 | 31,917 (0%) | 0% | 178.3 | 820,753 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 172.02 per share. | 01 Oct 2021 | 4,103 | 57,806 (0%) | 0% | 172.0 | 705,815 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 175.15 per share. | 01 Oct 2021 | 3,602 | 45,349 (0%) | 0% | 175.1 | 630,878 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 173.16 per share. | 01 Oct 2021 | 3,002 | 54,804 (0%) | 0% | 173.2 | 519,834 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 167.88 per share. | 01 Oct 2021 | 2,801 | 67,371 (0%) | 0% | 167.9 | 470,240 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 171.34 per share. | 01 Oct 2021 | 2,602 | 61,909 (0%) | 0% | 171.3 | 445,814 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 176.24 per share. | 01 Oct 2021 | 2,601 | 42,748 (0%) | 0% | 176.2 | 458,388 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 180.42 per share. | 01 Oct 2021 | 2,541 | 28,053 (0%) | 0% | 180.4 | 458,457 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 169.05 per share. | 01 Oct 2021 | 1,959 | 65,412 (0%) | 0% | 169.1 | 331,175 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 181.21 per share. | 01 Oct 2021 | 1,600 | 26,453 (0%) | 0% | 181.2 | 289,934 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 189.47 per share. | 01 Oct 2021 | 1,502 | 24,351 (0%) | 0% | 189.5 | 284,584 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 179.29 per share. | 01 Oct 2021 | 1,323 | 30,594 (0%) | 0% | 179.3 | 237,200 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 166.62 per share. | 01 Oct 2021 | 1,100 | 70,172 (0%) | 0% | 166.6 | 183,286 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 165.68 per share. | 01 Oct 2021 | 904 | 71,272 (0%) | 0% | 165.7 | 149,777 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 170.07 per share. | 01 Oct 2021 | 901 | 64,511 (0%) | 0% | 170.1 | 153,233 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 164.74 per share. | 01 Oct 2021 | 703 | 72,176 (0%) | 0% | 164.7 | 115,812 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 190.63 per share. | 01 Oct 2021 | 472 | 23,879 (0%) | 0% | 190.6 | 89,978 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 182.40 per share. | 01 Oct 2021 | 300 | 26,153 (0%) | 0% | 182.4 | 54,721 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 183.61 per share. | 01 Oct 2021 | 192 | 25,961 (0%) | 0% | 183.6 | 35,253 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 187.95 per share. | 01 Oct 2021 | 100 | 25,853 (0%) | 0% | 188.0 | 18,795 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 185.75 per share. | 01 Oct 2021 | 8 | 25,953 (0%) | 0% | 185.8 | 1,486 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2021 | 6,546 | 6,546 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2021 | 6,546 | 27,041 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 248.16 per share. | 26 Sep 2021 | 3,162 | 23,879 (0%) | 0% | 248.2 | 784,682 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 27,439 | 0 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 121.00 per share. | 01 Jul 2021 | 27,439 | 73,054 (0%) | 0% | 121 | 3,320,119 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 25,120 | 0 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.60 per share. | 01 Jul 2021 | 25,120 | 45,615 (0%) | 0% | 36.6 | 919,392 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.60 per share. | 01 Jul 2021 | 19,879 | 55,555 (0%) | 0% | 36.6 | 727,571 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 19,879 | 25,120 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 121.00 per share. | 01 Jul 2021 | 17,560 | 73,115 (0%) | 0% | 121 | 2,124,760 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 17,560 | 27,439 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.60 per share. | 01 Jul 2021 | 15,181 | 35,676 (0%) | 0% | 25.6 | 388,634 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 15,181 | 0 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 214.13 per share. | 01 Jul 2021 | 12,917 | 28,808 (0%) | 0% | 214.1 | 2,765,878 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 213.07 per share. | 01 Jul 2021 | 12,703 | 41,725 (0%) | 0% | 213.1 | 2,706,641 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 217.84 per share. | 01 Jul 2021 | 9,969 | 34,252 (0%) | 0% | 217.8 | 2,171,652 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 212.29 per share. | 01 Jul 2021 | 7,616 | 59,226 (0%) | 0% | 212.3 | 1,616,784 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 218.77 per share. | 01 Jul 2021 | 7,423 | 26,829 (0%) | 0% | 218.8 | 1,623,942 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 214.97 per share. | 01 Jul 2021 | 6,984 | 21,824 (0%) | 0% | 215.0 | 1,501,337 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 212.15 per share. | 01 Jul 2021 | 6,419 | 54,428 (0%) | 0% | 212.2 | 1,361,808 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 210.02 per share. | 01 Jul 2021 | 6,105 | 64,964 (0%) | 0% | 210.0 | 1,282,190 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 215.74 per share. | 01 Jul 2021 | 5,190 | 47,215 (0%) | 0% | 215.7 | 1,119,694 | Common Stock |
| Novavax, Inc. | Stanley Charles Erck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 219.76 per share. | 01 Jul 2021 | 5,031 | 21,798 (0%) | 0% | 219.8 | 1,105,615 | Common Stock |